Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

Study Results Demonstrated Significant Weight Loss in Obese Patients Treated with Qnexa

MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the previously reported 28-week phase 3 EQUATE trial of Qnexa(TM) in obese patients are being presented today at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. The results, titled "Weight Loss at 6 Months with VI-0521 Treatment," will be presented at the Hot Topic poster session by Donna H. Ryan, M.D., Associate Executive Director for Clinical Research, Pennington Biomedical Research Center in Baton Rouge, LA. The presentation marks the first time these results have been shared with the medical community at a major medical meeting.

The phase 3 EQUATE trial evaluated weight loss achieved with two doses of Qnexa versus that achieved with placebo among 756 patients over 28 weeks. Patients taking full-dose and mid-dose Qnexa achieved an average weight loss of 9.2 percent and 8.5 percent, respectively, as compared to 1.7 percent reported for the placebo group. All results were evaluated using ITT-LOCF, the method of analysis required by the U.S. Food and Drug Administration.

"Obesity has reached epidemic proportions, affecting more than 300 million people worldwide and contributing to increased prevalence of life-threatening illnesses such as hypertension, diabetes, cardiovascular disease and stroke. Patients are in urgent need of new, safe and effective tools to help them achieve the weight loss critical to their health and wellbeing," said Dr. Ryan. "The weight loss seen in patients taking Qnexa, over just 28 weeks, is encouraging for those of us in the medical community treat
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 8 Aton Pharma, Inc., a diversified ... has joined the company as Vice President, Commercial Operations ... A. Fishbein assumes the same role for the Ophthalmic ... LLC, Aton is focused on the development and commercialization of ...
... , , , , , ... , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink ... of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that ... the fiscal year ended, October 31, 2009 on time. ...
... ... Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and marketer of "Clean ... Laboratory and Research Division “TerraSolv SA” has received final approval ... additional $1.3 Million laboratory service contract with the Nigerian National ...
... in the gut, triggering bone formation , MONDAY, Feb. 8 ... the gut cured osteoporosis in lab mice and rats, a ... serotonin in the gut hinders bone formation. Most current drugs ... build bone. , "New therapies that inhibit the production of ...
... divide abnormally, researchers say , MONDAY, Feb. 8 (HealthDay News) ... week may have double the risk of developing deadly pancreatic ... But the overall number of people developing the malignancy remains ... new cases last year. , "Soft drinks are linked with ...
... , WOONSOCKET, ... CVS ) today announced record revenues, operating profit, and ... ended December 31, 2009 . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... of 2009, increased $1.7 billion to $25.8 billion , up ...
Cached Medicine News:Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 3Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 16Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 17Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 18Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 19Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 20Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 21Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 22Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 23Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 24Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 25Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 26
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: